Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
206.05
-0.73 (-0.35%)
Oct 28, 2026, 9:45 AM EDT - Market open
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $1.21B in the quarter ending June 30, 2026, with 15.55% growth. This brings the company's total for the last twelve months to $4.60B, up 12.59% year-over-year. In the year 2025, Jazz Pharmaceuticals had annual revenue of $4.27B with 4.88% growth. That makes Jazz Pharmaceuticals the 2,787th largest company in the world by revenue and 802nd in the United States.
Revenue (ttm)
$4.60B
Revenue Growth
+12.59%
P/S Ratio
2.92
Revenue / Employee
$1,592,140
Employees
2,890
Market Cap
13.38B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Jazz Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.27B | 198.64M | 4.88% |
| Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
| Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
| Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
| Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
| Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
| Dec 31, 2019 | 2.16B | 270.84M | 14.32% |
| Dec 31, 2018 | 1.89B | 272.23M | 16.82% |
| Dec 31, 2017 | 1.62B | 130.72M | 8.79% |
| Dec 31, 2016 | 1.49B | 163.17M | 12.32% |
| Dec 31, 2015 | 1.32B | 151.93M | 12.95% |
| Dec 31, 2014 | 1.17B | 300.45M | 34.44% |
| Dec 31, 2013 | 872.42M | 286.44M | 48.88% |
| Dec 31, 2012 | 585.98M | 313.70M | 115.21% |
| Dec 31, 2011 | 272.28M | 98.50M | 56.68% |
| Dec 31, 2010 | 173.78M | 45.33M | 35.29% |
| Dec 31, 2009 | 128.45M | 60.94M | 90.26% |
| Dec 31, 2008 | 67.51M | 2.21M | 3.39% |
| Dec 31, 2007 | 65.30M | 20.45M | 45.58% |
| Dec 31, 2006 | 44.86M | 23.41M | 109.20% |
| Dec 31, 2005 | 21.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.41B |
| Exelixis | 2.44B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Ascendis Pharma | 1.20B |
| Insmed | 1.14B |
| Corcept Therapeutics | 830.81M |
JAZZ News
- 2 hours ago - Jazz Pharmaceuticals price target raised to $300 from $276 at JPMorgan - TheFly
- 4 days ago - Jazz announces updated overall survival results from HERIZON-GEA-01 trial - TheFly
- 4 days ago - Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026 - PRNewsWire
- 7 days ago - Jazz Pharmaceuticals price target lowered to $314 from $322 at Morgan Stanley - TheFly
- 8 days ago - Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 - PRNewsWire
- 19 days ago - Jazz Pharmaceuticals price target raised to $313 from $307 at BofA - TheFly
- 20 days ago - Jazz Pharmaceuticals price target lowered to $296 from $299 at RBC Capital - TheFly
- 21 days ago - Jazz Pharmaceuticals price target raised to $286 from $281 at Truist - TheFly